Brodalumab (AMG 827), an anti-IL-17R mAb, is also currently being studied in clinical trials in RA, PsA, psoriasis, CD and asthma, with clinical improvement in psoriasis in phase II [46]. Here, IL17RA is linked to psoriasis.